The Danish pharma company, Novo Nordisk is planning to launch its new diabetic insulin called 'GLP1 analogue insulin', which would perform intermediate action, in the Indian and other markets soon. 

Novo Nordisk plans to launch its new diabetic insulin called 'GLP1 analogue insulin', which would perform intermediate action in the Indian and other markets. There are mainly three types of insulin available in the market for diabetic patients like short action, long action and intermediate action. Nova Nordisk is concentrating only on the intermediate actions insulin as it is more comfortable for a diabetic patient.

In this area, the company has three brands — Nova Mix, Nova Rapid and Levimir insulins. Out of these, Levimer is of intermediate action, which shows its effect for 24 hours within the body. The company official also claimed that their main driver for their business was modern insulin.